PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩70 per share · Prices as of the 2026-10-02 close
Aju IB Investment posted a sharp jump in quarterly operating profit in the second quarter of 2026 on higher performance fees and revaluation gains from overseas investment assets, with the exit (IPO) pipeline of its domestic and overseas portfolio emerging as the key variable for second-half earnings.
Q2 2026 operating profit reached KRW 38.1bn (owners' net income KRW 30.1bn), a sharp sequential increase, taking first-half cumulative operating profit to a record level
Through its US subsidiary Solasta Ventures, the company has invested in overseas assets such as SpaceX and Arcellx, with expectations of stake revaluation upon IPO/exit acting as a key driver of share price volatility
Two funds totaling roughly KRW 520bn were completed in 2025, and AUM expanded to about KRW 2.5tn as of mid-2026, with continued growth in both the PE and venture segments
Three portfolio companies—Kanaph Therapeutics, IM Biologics, and Mezoo—listed in the first half of 2026, and several more are in the listing process for the second half
2025 annual operating cash flow was negative KRW 1.1bn despite a net profit, reflecting cash-generation pressure inherent in an earnings structure driven by valuation gains and performance fees
Aju IB Investment began operations after registering as a new technology business finance company in 1998 and listed on KOSDAQ in November 2018 as one of Korea's first-generation venture capital firms.
Its business structure comprises new-technology business finance under the Specialized Credit Finance Business Act, small and medium business investment company/limited liability company operations under the Venture Investment Promotion Act, and management of institutional private equity funds (PEF) registered with the Financial Supervisory Service as general partner.
Venture fund AUM stands at roughly KRW 1.44tn and PE (PEF) AUM at roughly KRW 998bn, giving the firm a dual asset structure built on venture and PE, with total AUM expanding to about KRW 2.5tn as of mid-2026.
The company elevated its accelerator (AC) unit to a full division in 2026 to strengthen early-stage investment capabilities.
Overseas investment activity began in 2013 with a focus on the US bio/healthcare sector, and through its US subsidiary Solasta Ventures, established in 2019 with a presence in Silicon Valley and Boston, the firm has invested in SpaceX and Arcellx among others.
Its domestic portfolio includes large private companies such as Yanolja and Viva Republica (Toss), providing additional future IPO catalysts.
The largest shareholder is Aju Corporation, holding roughly 60% of shares, while listed VC peers include Mirae Asset Venture Investment, Woori Technology Investment, and StoneBridge Ventures.
In February 2026, the firm won the 'Best Private Equity House' award at the '2026 Korea Venture Capital Awards' hosted by TheBell and the Korea Venture Capital Association, reinforcing its market standing in the PE segment.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | ₩3.1B | — |
| 2025Q3 | — | ₩2.3B | — |
| 2025Q4 | — | ₩5.7B | — |
| 2026Q1 | — | ₩8.1B | — |
| 2026Q2 | — | ₩38.1B | — |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | — | ₩4.8B | ₩2B | — | 1.1% | 53.3% |
| 2023 | — | ₩17.7B | ₩16.6B | — | 7.5% | 37.2% |
| 2024 | — | ₩8.4B | ₩8.3B | — | 3.6% | 30.9% |
| 2025 | — | ₩11.9B | ₩8.3B | — | 3.3% | 26.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Looking at annual results, owners' net income moved from KRW 2.0bn in 2022 to KRW 16.6bn in 2023, then KRW 8.3bn in 2024 and KRW 8.3bn in 2025, while operating profit rose sharply from KRW 4.8bn in 2022 to KRW 17.7bn in 2023 before adjusting to KRW 8.4bn in 2024 and recovering to KRW 11.9bn in 2025.
The debt ratio steadily declined from 53.3% in 2022 to 26.8% in 2025, indicating an improving balance-sheet structure. On a quarterly basis, operating profit rose gradually from KRW 3.1bn in Q2 2025, to KRW 2.3bn in Q3, KRW 5.7bn in Q4, before jumping to KRW 8.1bn in Q1 2026 and KRW 38.1bn in Q2 2026.
Owners' net income likewise surged from KRW 2.4bn in Q2 2025 to KRW 30.1bn in Q2 2026, a move attributed to increased fund performance fees and valuation gains on overseas investment assets including SpaceX.
Owners' net income over the most recent four quarters (Q3 2025 through Q2 2026) totaled about KRW 41.5bn, exceeding several prior full-year net income levels within a single rolling four-quarter window.
However, 2025 annual operating cash flow was negative KRW 1.1bn, a marked contraction from KRW 24.1bn in 2024 and KRW 43.0bn in 2023; the shift to negative cash flow despite a reported net profit suggests earnings were driven substantially by non-cash factors such as valuation gains and performance-fee recognition rather than realized cash.
This earnings structure indicates that quarterly volatility could widen further depending on the timing of portfolio company listings and overseas asset exits.
Korea's venture capital industry is seen entering a phase where policy-driven capital supply, including the National Growth Fund, and a simultaneous recovery across fund formation, investment, and exit are expected in 2026.
The KOSDAQ IPO market began normalizing gradually from the second half of 2025, and the government has pursued reforms to KOSDAQ listing and delisting rules, expanded technology special listings, and introduced business development companies (BDCs) in an effort to redefine KOSDAQ as an exit market for venture capital.
However, an August 2026 report noted that new listings in the first half numbered only 17, less than half of the 38 recorded a year earlier, with proceeds down 49% year-on-year, showing that exit-market tightness has also weighed on investment sentiment.
In response, the Korea Financial Investment Association and securities firms agreed to jointly pursue up to KRW 1tn in venture secondary investments over the next three years to address the IPO-concentrated exit structure.
Industry observers note growing emphasis on DPI (distributions to paid-in capital), a measure of actual cash returned, and say the relationship-based co-investment model common among Korean VCs is facing pressure to evolve.
Peer listed VCs such as Mirae Asset Venture Investment and Woori Technology Investment share similar thematic exposure through past investments in large global assets like SpaceX, while Aju IB Investment differentiates its position through a multi-stage strategy spanning venture, PE, and accelerator investing alongside overseas bio and aerospace asset exposure.
The company has positioned 2026 as the year its accelerator and PE investment segments scale up alongside its core venture business, targeting execution of at least KRW 380bn in investments this year, of which about 15% is planned for global companies.
In the PE segment, a project fund is currently being formed, and the company plans to pursue a new venture fund linked to the National Growth Fund as well as the 'Aju-Solasta Life Science 5.0 Fund' for expanded overseas investment in the second half.
It also plans to form the 'Aju Good Ultra-Gap 2.0 Fund' in the second half of 2026 to finance early-stage investments.
On the exit pipeline, portfolio companies Lemon Healthcare and Delicious listed in July and August 2026 respectively, while Dabeeo, a specialty fine-chemical maker, and MBD are currently in the listing process, and NexI is preparing to file for a preliminary listing review in the second half.
Overseas, the company is reportedly working to exit its Arcellx investment targeting a multiple of eight times or more, while for SpaceX, with investment amount and stake undisclosed, the timing and realization of a listing remain the key variable for any future stake revaluation.
CEO Kim Ji-won has stated that in a volatile market environment, the ability to select portfolio companies based on fundamentals and growth potential is critical, outlining a strategy of pursuing growth sectors such as AI, bio, and aerospace alongside quality overseas assets.
With owners' net income over the trailing four quarters exceeding several prior full-year net income levels, market attention has focused on whether this earnings expansion reflects sustainable profitability or is driven by one-off valuation gains and performance fees.
The price-to-book ratio trades in a range that carries a certain premium over net asset value, reflecting market expectations for the future value of unlisted overseas assets such as the SpaceX stake beyond current book value.
On the dividend side, the per-share cash dividend has remained at a modest level even during the earnings recovery, suggesting the dividend yield is not notably high relative to industry peers.
Taken together, the stock's valuation history over recent years shows it has tended to respond more sensitively to portfolio exit events and their timing than to reported accounting results alone.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
The surge in Q2 2026 operating profit to KRW 38.1bn reflects both higher fund performance fees and valuation gains recognized on overseas investment assets such as SpaceX. Owners' net income over the trailing four quarters totaled about KRW 41.5bn, well above prior annual net income levels. AUM has expanded to roughly KRW 2.5tn, also growing the stable management-fee income base.
The company formed its largest-ever PEF of KRW 313bn in 2025, and PE AUM reached about KRW 998bn, approaching venture fund AUM.
In 2026 it elevated its accelerator unit to a full division to strengthen early-stage investing and won the Best PE House award at the 2026 Korea Venture Capital Awards, bolstering its market reputation.
Three portfolio companies—Kanaph Therapeutics, IM Biologics, and Mezoo—listed in the first half of 2026, followed by Lemon Healthcare and Delicious. Dabeeo and MBD are in the listing process, and NexI is preparing a preliminary review, leaving room for further exit events in the second half.
The Q2 2026 earnings surge is understood to rely heavily on valuation gains and performance-fee recognition, which can diverge from realized cash flow. Indeed, 2025 annual operating cash flow was negative KRW 1.1bn despite a reported net profit.
If the actual sale or monetization of overseas unlisted assets is delayed, the gap between accounting profit and cash inflow could resurface.
An August 2026 report noted that first-half new listings numbered only 17, less than half of the prior-year's 38, with IPO proceeds down 49%. Large fundraising deals have also reportedly slowed sharply since June-July, suggesting the second-half KOSDAQ exit environment may not necessarily be smooth.
Aju IB Investment's investment amount and stake in SpaceX have not been disclosed to date. This makes it difficult for outside observers to precisely estimate the actual profit contribution, and a meaningful gap between market expectations and actual realized gains cannot be ruled out.
Fair-value assessment of unlisted portfolio assets carries significant volatility due to market conditions and limited exchange data, and fluctuations in the KOSDAQ index or global equity markets directly affect valuation gains and losses.
A delay in the listing of large overseas assets such as SpaceX, or a downward valuation adjustment, could reduce reported accounting profit.
Regulatory changes related to new-technology business finance laws, the Venture Investment Promotion Act, and KOSDAQ listing/delisting system reforms can affect fund formation and investment/exit strategy.
Implementation details of new frameworks such as BDCs have not yet been finalized, leaving uncertainty in the policy execution process.
With largest shareholder Aju Corporation holding roughly 60% of shares, the free float is relatively limited, and in April 2026 the Korea Exchange reportedly issued a pre-designation notice for investment caution status following a short-term price surge. Heightened short-term volatility driven by thematic trading flows is a factor investors should be mindful of.
Check whether the 'Aju Good Ultra-Gap 2.0 Fund' and the new National Growth Fund-linked fund are successfully formed, to gauge the scale of management-fee base expansion.
Confirm whether portfolio companies in the listing process, such as Dabeeo and MBD, actually list and on what timeline, along with any stake-sale plans, to gauge the scale of realized exit gains.
Watch for the preliminary Q3 earnings disclosure to see whether the surge in performance fees and valuation gains seen in Q2 continues or normalizes.
Track SpaceX's actual IPO progress and whether investment amount and stake details are disclosed, to assess the reliability of information related to any stake revaluation.
Check NexI's preliminary listing review filing and outcome, as well as progress on the Arcellx exit, to monitor for additional realization events.
As one of Korea's first-generation venture capital firms, Aju IB Investment operates on two pillars: a multi-stage investment strategy spanning venture, PE, and accelerator investing, and exposure to overseas bio and aerospace assets through its Solasta Ventures subsidiary.
While operating profit and net income rose sharply in Q2 2026, this appears to stem substantially from higher fund performance fees and valuation gains on overseas assets such as SpaceX, and the negative operating cash flow recorded in the same period suggests the quality of earnings warrants further scrutiny.
The continued listing of domestic portfolio companies in the first half, with several more pending in the second half, is a positive for exit-pipeline diversification, but the signal of contracting new listings and IPO proceeds in the KOSDAQ exit market during the first half of 2026 is worth noting.
With SpaceX-related investment amount and stake still undisclosed, precisely estimating the actual profit contribution remains difficult for outside observers, and given the high ownership concentration of the largest shareholder and limited free float, short-term supply-demand driven price volatility has also been observed.
On balance, the stock presents a mix of bullish factors—an earnings-recovery trajectory and a diversified set of exit events—alongside bearish considerations including the non-recurring nature of recent profits, undisclosed information, and signs of exit-market tightness.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.